PDS Biotechnology (PDSB) stock price is up over 61% this past year. PDS Biotechnology director, president, and CEO, Dr. Frank Bedu, weighs in on the latest trial results that indicated 100% clinical response for treatment of cervical cancer patients with large tumors using a combination of PDS101 with standard-of-care chemoradiotherapy. All patients had a tumor shrinkage of 60% or greater.
The Watch List
22 Jan 2023
SHARE
Trading 360
09 Nov 2023
Morning Trade Live
09 Jan 2024
Trading 360
03 Jan 2024
Morning Trade Live
14 Dec 2023
Market On Close
24 Oct 2023
Morning Trade Live
06 Dec 2023